Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Feb 24;12:3122. doi: 10.1038/s41598-022-06197-5

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

RFC2 expression correlated with clinicopathological features in our LGG samples. (A) The immunohistochemistry images showing the relative expression of RFC2 in LGG tissues and benign brain tumor tissues (Original magnification, × 400). (B) RFC2 expression levels in LGG tissues (n = 69) and benign brain tumor tissues (n = 10) were evaluated by immunohistochemistry analysis. (C–J) The associations of RFC2 expression with clinicopathological factors, including age (C), gender (D), WHO grade (E), pathological classification (F), IDH1 mutation status (G), radiation therapy history (H), chemotherapy history (I), and seizure history (J). (K) Heatmap displaying the correlation between RFC2 expression and clinicopathological features in our LGG patients. (L,M) Kaplan–Meier survival analyses showing the relationships of RFC2 expression with overall survival (OS) (L) and disease-free survival (DFS) (M) in LGG patients. (*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001).